Inovio Pharmaceuticals (INO +14.8%) pops after announcing Phase I clinical results indicating...

|About: Inovio Pharmaceuticals, Inc. (INO)|By:, SA News Editor

Inovio Pharmaceuticals (INO +14.8%) pops after announcing Phase I clinical results indicating that its DNA-based synthetic vaccine VGX-3100 is not only capable of boosting immune responses to antigens from high risk types of human papillomavirus infection, but also killing cells changed by the virus into precancerous dysplasias.